Akari Therapeutics (AKTX) Other Non Operating Income (2014 - 2026)
Akari Therapeutics (AKTX) reported Other Non Operating Income of $44000.0 for Q1 2026, up 135.2% on a YoY basis from $18707.5 in Q1 2025, and down 91.6% sequentially from $524000.0 in Q4 2025.
Akari Therapeutics (AKTX) Other Non Operating Income (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 9 years of Other Non Operating Income data on file, last reported at $44000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income rose 135.2% year-over-year to $44000.0; the trailing twelve-month figure through Mar 2026 stood at $594000.0 (up 102.12% YoY), and the FY2025 full-year result was -$443000.0, down 121.25% from the prior year.
- Other Non Operating Income slipped to $44000.0 in Q1 2026, from $524000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $560000.0 in Q2 2023 to a low of -$28.0 million in Q4 2024.
- A 4-year average of -$2.5 million and a median of -$11000.0 in 2023 frame the typical range for Other Non Operating Income.
- Peak annual rise in Other Non Operating Income reached 236.36% in 2024, while the deepest fall reached 1954.55% in 2024.
- Tracing AKTX's Other Non Operating Income over 4 years: stood at -$5.9 million in 2023, then sank by 374.05% to -$28.0 million in 2024, then surged by 101.87% to $524000.0 in 2025, then sank by 91.6% to $44000.0 in 2026.
- Business Quant data shows AKTX's Other Non Operating Income at $44000.0 in Q1 2026, $524000.0 in Q4 2025, and $76000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44,000.00 |
| Dec 31, 2025 | 524,000.00 |
| Sep 30, 2025 | 76,000.00 |
| Jun 30, 2025 | -50,000.00 |
| Mar 31, 2025 | -125,000.00 |
| Dec 31, 2024 | -28.01 Mn |
| Sep 30, 2024 | 30,000.00 |
| Jun 30, 2024 | 91,000.00 |
| Mar 31, 2024 | -226,000.00 |
| Dec 31, 2023 | -5.91 Mn |
| Sep 30, 2023 | -22,000.00 |
| Jun 30, 2023 | 560,000.00 |
| Mar 31, 2023 | -11,000.00 |
| Dec 31, 2020 | 159,442.00 |
| Sep 30, 2020 | 1.00 Mn |
| Jun 30, 2020 | 27,992.00 |
| Mar 31, 2020 | 949,456.00 |
| Dec 31, 2019 | 4,733.00 |
| Sep 30, 2019 | 37,209.00 |
| Jun 30, 2019 | 86,438.00 |